

**REMARKS**

Allowed claims 13 and 63 are pending in the current application. Claims 12, 14-16, 18-35, 37, 39, 41-48, 51, 53-60 and 62 have been cancelled in this Response.

Applicants expressly reserve the right to pursue cancelled subject matter in continuing applications.

***Claim Rejections under 35 USC § 112 – Scope of Enablement***

Claims 12, 14-16, 18-34, 60 and 62 were rejected under 35 U.S.C. § 112, first paragraph. To expedite prosecution Claims 12, 14-16, 18-34, 60 and 62 are cancelled herein. Applicants respectfully submit that this rejection is moot and request that this rejection be withdrawn.

***Claim Rejections under 35 USC § 112 – Written Description***

Claims 12, 14-16, 18-34, 60 and 62 were rejected under 35 U.S.C. § 112, first paragraph. To expedite prosecution Claims 12, 14-16, 18-34, 60 and 62 are cancelled herein. Applicants respectfully submit that this rejection is moot and request that this rejection be withdrawn.

***Claim Rejections under 35 USC § 112 – 2<sup>nd</sup> Paragraph***

Claims 12, 14-16, 18-34, 60 and 62 were rejected under 35 U.S.C. § 112, second paragraph. To expedite prosecution Claims 12, 14-16, 18-34, 60 and 62 are cancelled herein. Applicants respectfully submit that this rejection is moot and request that this rejection be withdrawn.

**CONCLUSION**

Should any outstanding issues remain, the Examiner is encouraged to contact Applicants' undersigned representative.

Respectfully submitted:

Date: February 15, 2010  
GlaxoSmithKline Inc.  
Corporate Intellectual Property  
Five Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709  
Tel. (919) 483-1891  
Fax: (919) 483-7988

  
Alice P. Bradney  
Attorney for Applicants  
Reg. No. 51,491